Lead Product(s) : TMS-007
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Biogen
Deal Size : $353.0 million
Deal Type : Acquisition
Details : Biogen exercised its option to acquire TMS-007, an investigational drug for acute ischemic stroke, from TMS. Biogen’s decision to acquire TMS-007 was based on positive data from a Phase 2a study.
Product Name : TMS-007
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 05, 2021
Lead Product(s) : TMS-007
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Biogen
Deal Size : $353.0 million
Deal Type : Acquisition
Lead Product(s) : Vandefitemcel
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Of the 51 patients in the treatment group that received SB623, improvement was seen in 49%, versus in 19% of 26 patients in the control group that received sham surgery, the difference between the two groups was statistically significant.
Product Name : SB623
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
September 14, 2020
Lead Product(s) : Vandefitemcel
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable